Skip to main content

Table 1 Characteristics of the patients at baseline

From: N-acetylcysteine plus deferoxamine for patients with prolonged hypotension does not decrease acute kidney injury incidence: a double blind, randomized, placebo-controlled trial

Characteristic

Placebo (n = 40)

NAC + DFX (n = 40)

Age, years, mean ± SD

56 ± 14

51 ± 16

Male sex, n (%)

23 (57)

20 (50)

Charlson comorbidity score, mean ± SD

2.4 ± 2.1

2.6 ± 2.3

Medical admission, n (%)

33 (82)

32 (80)

Sepsis at enrollment, n (%)

20 (50)

21 (52)

Cardiogenic shock, n (%)

10 (25)

9 (22)

Trauma, n (%)

6 (15)

7 (17)

APACHE II score, mean ± SD

19 ± 7

20 ± 7

SOFA score day 1, mean ± SD

9.4 ± 4

9.3 ± 3.7

Creatinine at enrollment, mean ± SD

1.0 ± 0.6

1.2 ± 1.7

AKI at admission, yes, n (%)

14 (35)

12 (30)

Mechanical ventilation at enrolment, yes, n (%)

25 (62)

23 (58)

Need for vasoactive drug, yes, n (%)

34 (85)

35 (87)

  1. NAC + DFX N-acetylcysteine plus deferoxamine, AKI acute kidney injury, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, SD standard deviation